APA (7th ed.) Citation

Hehlmann, R., Saußele, S., Fabarius, A., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., . . . Ho, A. D. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), . https://doi.org/10.1038/leu.2017.253

Chicago Style (17th ed.) Citation

Hehlmann, Rüdiger, Susanne Saußele, Alice Fabarius, Katharina Kohlbrenner, Astghik Voskanyan, Sébastien Rinaldetti, Wolfgang Seifarth, Birgit Spiess, and Anthony Dick Ho. "Assessment of Imatinib as First-line Treatment of Chronic Myeloid Leukemia: 10-year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants." Leukemia 31, no. 11 (2017). https://doi.org/10.1038/leu.2017.253.

MLA (9th ed.) Citation

Hehlmann, Rüdiger, et al. "Assessment of Imatinib as First-line Treatment of Chronic Myeloid Leukemia: 10-year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants." Leukemia, vol. 31, no. 11, 2017, https://doi.org/10.1038/leu.2017.253.